Barclays Has Lowered Expectations for Bruker (NASDAQ:BRKR) Stock Price

Bruker (NASDAQ:BRKR) had its target price cut by equities research analysts at Barclays from $50.00 to $46.00 in a report released on Thursday,Benzinga reports. The firm currently has an “overweight” rating on the medical research company’s stock. Barclays‘s price objective would indicate a potential upside of 21.73% from the company’s current price.

BRKR has been the topic of several other research reports. Stifel Nicolaus cut their price objective on Bruker from $57.00 to $48.00 and set a “hold” rating on the stock in a report on Thursday. The Goldman Sachs Group reduced their price target on shares of Bruker from $50.00 to $45.00 and set a “neutral” rating for the company in a research report on Thursday. Guggenheim reiterated a “buy” rating on shares of Bruker in a research report on Monday, February 24th. Wells Fargo & Company reduced their target price on Bruker from $75.00 to $60.00 and set an “overweight” rating for the company in a report on Thursday, April 17th. Finally, Citigroup lowered their price target on Bruker from $75.00 to $50.00 and set a “buy” rating on the stock in a report on Monday, April 7th. Six investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $60.10.

Bruker Stock Down 6.7 %

BRKR stock opened at $37.79 on Thursday. The company has a debt-to-equity ratio of 1.15, a current ratio of 1.60 and a quick ratio of 0.77. The firm has a market cap of $5.73 billion, a PE ratio of 49.72, a P/E/G ratio of 2.16 and a beta of 1.23. Bruker has a 12 month low of $34.10 and a 12 month high of $79.78. The firm has a 50 day simple moving average of $41.26 and a 200 day simple moving average of $51.21.

Bruker (NASDAQ:BRKR) last released its quarterly earnings data on Wednesday, May 7th. The medical research company reported $0.47 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.01. The business had revenue of $801.40 million during the quarter, compared to analyst estimates of $763.83 million. Bruker had a return on equity of 21.01% and a net margin of 3.36%. The company’s revenue was up 11.0% compared to the same quarter last year. During the same period last year, the company posted $0.53 EPS. Equities research analysts forecast that Bruker will post 2.69 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Bruker

Several institutional investors have recently made changes to their positions in BRKR. Chicago Partners Investment Group LLC acquired a new position in Bruker in the first quarter worth approximately $238,000. Charles Schwab Investment Management Inc. increased its stake in shares of Bruker by 5.8% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 926,790 shares of the medical research company’s stock worth $38,684,000 after purchasing an additional 50,537 shares during the last quarter. Annis Gardner Whiting Capital Advisors LLC bought a new position in shares of Bruker during the 1st quarter valued at $42,000. New Age Alpha Advisors LLC lifted its stake in shares of Bruker by 8.8% in the 1st quarter. New Age Alpha Advisors LLC now owns 11,218 shares of the medical research company’s stock valued at $468,000 after purchasing an additional 904 shares during the last quarter. Finally, ING Groep NV bought a new stake in Bruker in the first quarter worth $7,605,000. 79.52% of the stock is currently owned by institutional investors and hedge funds.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.